G Frank Gerberick

Summary

Affiliation: The Procter and Gamble Company
Country: USA

Publications

  1. ncbi Local lymph node assay: differentiating allergic and irritant responses using flow cytometry
    G F Gerberick
    Miami Valley Laboratories, The Procter and Gamble Company, Cincinnati, Ohio 45239 8707, USA
    Methods 19:48-55. 1999
  2. ncbi Development of a peptide reactivity assay for screening contact allergens
    G Frank Gerberick
    Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45253 8707, USA
    Toxicol Sci 81:332-43. 2004
  3. ncbi Compilation of historical local lymph node data for evaluation of skin sensitization alternative methods
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Innovation Center, P O Box 538707, Cincinnati, OH 45253 8707, USA
    Dermatitis 16:157-202. 2005
  4. ncbi Local lymph node assay (LLNA) for detection of sensitization capacity of chemicals
    G Frank Gerberick
    The Procter and Gamble Company, Central Product Safety Department, Miami Valley Innovation Center, P O Box 538707, Cincinnati, OH 45253, USA
    Methods 41:54-60. 2007
  5. ncbi Quantification of chemical peptide reactivity for screening contact allergens: a classification tree model approach
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Innovation Center, Cincinnati, OH 45252, USA
    Toxicol Sci 97:417-27. 2007
  6. ncbi A chemical dataset for evaluation of alternative approaches to skin-sensitization testing
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, OH 45253 8707, USA
    Contact Dermatitis 50:274-88. 2004
  7. ncbi Chemical reactivity measurement and the predicitve identification of skin sensitisers. The report and recommendations of ECVAM Workshop 64
    Frank Gerberick
    Procter and Gamble Company, Miami Valley Innovation Center, Cincinnati, OH 45253, USA
    Altern Lab Anim 36:215-42. 2008
  8. ncbi Use of a B cell marker (B220) to discriminate between allergens and irritants in the local lymph node assay
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Laboratories, P O Box 538707, Cincinnati, Ohio 4523 8707, USA
    Toxicol Sci 68:420-8. 2002
  9. ncbi Investigation of peptide reactivity of pro-hapten skin sensitizers using a peroxidase-peroxide oxidation system
    G Frank Gerberick
    Central Product Safety, Miami Valley Innovation Center, The Procter and Gamble Company, Cincinnati, Ohio 45253, USA
    Toxicol Sci 112:164-74. 2009
  10. ncbi Contact allergenic potency: correlation of human and local lymph node assay data
    G F Gerberick
    Human and Environmental Safety Division, Procter and Gamble, Cincinnati, OH 45252, USA
    Am J Contact Dermat 12:156-61. 2001

Detail Information

Publications38

  1. ncbi Local lymph node assay: differentiating allergic and irritant responses using flow cytometry
    G F Gerberick
    Miami Valley Laboratories, The Procter and Gamble Company, Cincinnati, Ohio 45239 8707, USA
    Methods 19:48-55. 1999
    ....
  2. ncbi Development of a peptide reactivity assay for screening contact allergens
    G Frank Gerberick
    Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45253 8707, USA
    Toxicol Sci 81:332-43. 2004
    ..5%). The data presented show that measuring peptide reactivity has utility for screening chemicals for their skin sensitization potency and thus potential for reducing our reliance on animal test methods...
  3. ncbi Compilation of historical local lymph node data for evaluation of skin sensitization alternative methods
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Innovation Center, P O Box 538707, Cincinnati, OH 45253 8707, USA
    Dermatitis 16:157-202. 2005
    ..In addition to accurately identifying skin sensitizers, the LLNA can also provide a reliable measure of relative sensitization potency, information that is pivotal to the successful management of human health risks...
  4. ncbi Local lymph node assay (LLNA) for detection of sensitization capacity of chemicals
    G Frank Gerberick
    The Procter and Gamble Company, Central Product Safety Department, Miami Valley Innovation Center, P O Box 538707, Cincinnati, OH 45253, USA
    Methods 41:54-60. 2007
    ....
  5. ncbi Quantification of chemical peptide reactivity for screening contact allergens: a classification tree model approach
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Innovation Center, Cincinnati, OH 45252, USA
    Toxicol Sci 97:417-27. 2007
    ..The results of these investigations reveal that measurement of peptide reactivity has considerable potential utility as a screening approach for skin sensitization testing, and thereby for reducing reliance on animal-based test methods...
  6. ncbi A chemical dataset for evaluation of alternative approaches to skin-sensitization testing
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, OH 45253 8707, USA
    Contact Dermatitis 50:274-88. 2004
    ..It is hoped that this dataset will accelerate the development, evaluation and eventual validation of new approaches to skin-sensitization testing...
  7. ncbi Chemical reactivity measurement and the predicitve identification of skin sensitisers. The report and recommendations of ECVAM Workshop 64
    Frank Gerberick
    Procter and Gamble Company, Miami Valley Innovation Center, Cincinnati, OH 45253, USA
    Altern Lab Anim 36:215-42. 2008
  8. ncbi Use of a B cell marker (B220) to discriminate between allergens and irritants in the local lymph node assay
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Laboratories, P O Box 538707, Cincinnati, Ohio 4523 8707, USA
    Toxicol Sci 68:420-8. 2002
    ..25. These data demonstrate that analysis of B220 expression in DLN may be useful in differentiating between allergen and irritant responses induced in chemically treated mice...
  9. ncbi Investigation of peptide reactivity of pro-hapten skin sensitizers using a peroxidase-peroxide oxidation system
    G Frank Gerberick
    Central Product Safety, Miami Valley Innovation Center, The Procter and Gamble Company, Cincinnati, Ohio 45253, USA
    Toxicol Sci 112:164-74. 2009
    ..This preliminary work shows the potential to incorporate an enzyme-mediated activation step for pro-haptens into an in chemico skin sensitization assay that results in the detection of all types of sensitizers...
  10. ncbi Contact allergenic potency: correlation of human and local lymph node assay data
    G F Gerberick
    Human and Environmental Safety Division, Procter and Gamble, Cincinnati, OH 45252, USA
    Am J Contact Dermat 12:156-61. 2001
    ..Preclinical testing for sensitization potential is critically important for hazard assessment before human exposure. The murine local lymph node assay (LLNA) is the most recently accepted test method for sensitization hazard assessment...
  11. ncbi A skin sensitization risk assessment approach for evaluation of new ingredients and products
    G F Gerberick
    Procter and Gamble Company, Miami Valley Laboratory, Cincinnati, OH 45253 8707, USA
    Am J Contact Dermat 11:65-73. 2000
    ..In summary, the skin sensitization risk assessment process described in this article allows one to carefully assess the skin sensitization potential of a new ingredient or product so that it can be safely introduced into the marketplace...
  12. ncbi Local lymph node assay: validation assessment for regulatory purposes
    G F Gerberick
    Miami Valley Laboratory, Procter and Gamble Company, the Zeneca Central Toxicology Laboratory, Alderley Park, Cincinnati, OH 45253 8707, USA
    Am J Contact Dermat 11:3-18. 2000
    ....
  13. ncbi The reduced local lymph node assay: the impact of group size
    Cindy A Ryan
    The Procter and Gamble Company, Cincinnati, OH 45253 8707, USA
    J Appl Toxicol 28:518-23. 2008
    ..It is concluded that a rLLNA with two mice/group would display decreased sensitivity and is inappropriate for use in hazard identification...
  14. ncbi The incorporation of lysine into the peroxidase peptide reactivity assay for skin sensitization assessments
    John A Troutman
    Central Product Safety, Miami Valley Innovation Center, The Procter and Gamble Company, Cincinnati, Ohio 45253, USA
    Toxicol Sci 122:422-36. 2011
    ..This approach has the potential to qualitatively and quantitatively evaluate an important mechanism in contact allergy for hazard and quantitative risk assessments without animal testing...
  15. ncbi Identification of gene expression changes induced by chemical allergens in dendritic cells: opportunities for skin sensitization testing
    Lucy A Gildea
    Central Product Safety Department, Miami Valley Innovation Center, The Procter and Gamble Company, Cincinnati, Ohio 45253 8707, USA
    J Invest Dermatol 126:1813-22. 2006
    ....
  16. ncbi Dendritic cells and skin sensitization: biological roles and uses in hazard identification
    Cindy A Ryan
    The Procter and Gamble Company, Miami Valley Innovation Center, Cincinnati, OH 45253 8707, USA
    Toxicol Appl Pharmacol 221:384-94. 2007
    ..This paper reports information that was presented during the Workshop...
  17. ncbi Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment
    Cindy A Ryan
    Miami Valley Innovation Center, Central Product Safety Department, The Procter and Gamble Company, Cincinnati, Ohio 45253 8707, USA
    Toxicol Sci 88:4-11. 2005
    ....
  18. ncbi Application of the risk assessment paradigm to the induction of allergic contact dermatitis
    Susan P Felter
    The Procter and Gamble Co, Miami Valley Laboratories, 11810 E Miami River Rd, Cincinnati, OH 45061, USA
    Regul Toxicol Pharmacol 37:1-10. 2003
    ....
  19. ncbi A modified human repeat insult patch test for extended mucosal tissue exposure
    Miranda A Farage
    The Procter and Gamble Company, Feminine Care Research and Development, Central Product Safety, Cincinnati, OH, USA
    Contact Dermatitis 49:214-5. 2003
  20. ncbi Gene expression changes in peripheral blood-derived dendritic cells following exposure to a contact allergen
    Cindy A Ryan
    Miami Valley Laboratories, Central Product Safety Department, The Procter and Gamble Company, P O Box 538707, Cincinnati, OH 45253, USA
    Toxicol Lett 150:301-16. 2004
    ..Additionally, it is hoped that some of the transcript changes identified through this approach will be shown to be suitable for use in the development of an in vitro predictive assay for contact sensitization...
  21. ncbi Relationship of CD86 surface marker expression and cytotoxicity on dendritic cells exposed to chemical allergen
    Ben C Hulette
    The Procter and Gamble Company, Miami Valley Laboratories, PO Box 538707, Cincinnati, OH 45253-8707, USA
    Toxicol Appl Pharmacol 209:159-66. 2005
    ....
  22. ncbi Quantitative risk assessment for the induction of allergic contact dermatitis: uncertainty factors for mucosal exposures
    Miranda A Farage
    The Procter and Gamble Company, Feminine Care Research and Development, Cincinnati, OH 45224, USA
    Contact Dermatitis 49:140-7. 2003
    ..We propose a 20-fold range in the default uncertainty factor used in the contact sensitization QRA when extrapolating from data derived from the skin to situations involving exposure to non-keratinized mucosal tissue...
  23. ncbi A review of the scientific basis for uncertainty factors for use in quantitative risk assessment for the induction of allergic contact dermatitis
    Susan P Felter
    The Procter and Gamble Co, Miami Valley Laboratories, Cincinnati, OH, USA
    Contact Dermatitis 47:257-66. 2002
    ..This paper provides an overview of each of these areas with an evaluation of the available scientific database to support an uncertainty factor in the range of 1-10 for each area...
  24. ncbi Elucidating changes in surface marker expression of dendritic cells following chemical allergen treatment
    Ben A Hulette
    The Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45253, USA
    Toxicol Appl Pharmacol 182:226-33. 2002
    ....
  25. ncbi Allergic contact dermatitis
    Ian Kimber
    Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, UK
    Int Immunopharmacol 2:201-11. 2002
    ..This article seeks to consider skin sensitization and ACD in holistic fashion, bridging experimental observations with clinical disease and basic mechanisms with practical toxicology...
  26. ncbi An evaluation of performance standards and non-radioactive endpoints for the local lymph node assay. The report and recommendations of ECVAM Workshop 65
    David Basketter
    St John's Institute of Dermatology, St Thomas' Hospital, London, UK
    Altern Lab Anim 36:243-57. 2008
  27. ncbi Preservatives and skin sensitization quantitative risk assessment
    David A Basketter
    Unilever, Colworth House, Sharnbrook, Bedfordshire, UK
    Dermatitis 19:20-7. 2008
    ....
  28. ncbi The local lymph node assay: current position in the regulatory classification of skin sensitizing chemicals
    David A Basketter
    St John s Institute of Dermatology, St Thomas Hospital, London, UK
    Cutan Ocul Toxicol 26:293-301. 2007
    ....
  29. ncbi Factors affecting thresholds in allergic contact dermatitis: safety and regulatory considerations
    David A Basketter
    SEAC, Unilever Colworth Laboratory, Sharnbrook, Bedford, UK
    Contact Dermatitis 47:1-6. 2002
    ..Thus, recommendations can be made concerning how these considerations can be embraced by those responsible for safety evaluation and for the shaping of regulations for skin sensitizing chemicals/formulations...
  30. ncbi Skin sensitisation
    David Basketter
    SEAC, Unilever Colworth Laboratory, Sharnbrook, Bedfordshire, MK44 1LQ, UK
    Altern Lab Anim 33:83-103. 2005
  31. ncbi Extrapolating local lymph node assay EC3 values to estimate relative sensitizing potency
    Cindy A Ryan
    The Procter and Gamble Company Cincinnati, Ohio, USA
    Cutan Ocul Toxicol 26:135-45. 2007
    ..Judicious use of this approach for extrapolating EC3 values can provide information on a likely potency classification for use in risk assessment and may avoid the need for repeat animal testing...
  32. ncbi B220 analysis with the local lymph node assay: proposal for a more flexible prediction model
    Catherine J Betts
    Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, UK
    J Appl Toxicol 27:506-10. 2007
    ..As a result a new prediction model is proposed in which reliance on the use of absolute thresholds is reduced, and in which small changes in control values can be better accommodated...
  33. ncbi Dendritic cells as a tool for the predictive identification of skin sensitisation hazard
    Silvia Casati
    ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, 21020 Ispra (VA, Italy
    Altern Lab Anim 33:47-62. 2005
  34. ncbi The local lymph node assay and skin sensitization: a cut-down screen to reduce animal requirements?
    Ian Kimber
    Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, UK
    Contact Dermatitis 54:181-5. 2006
    ..However, a detailed evaluation will be necessary to provide reassurance that a reduction in group size would provide adequate sensitivity across a range of skin sensitization potencies...
  35. ncbi Hapten-protein binding: from theory to practical application in the in vitro prediction of skin sensitization
    Maja Divkovic
    Unilever Colworth, Sharnbrook, Bedfordshire, UK
    Contact Dermatitis 53:189-200. 2005
    ....
  36. ncbi Categorical QSAR models for skin sensitization based on local lymph node assay measures and both ground and excited state 4D-fingerprint descriptors
    Jianzhong Liu
    College of Pharmacy, 1 University of New Mexico, MSC09 5360, Albuquerque, NM, 87131 0001, USA
    J Comput Aided Mol Des 22:345-66. 2008
    ..These EMAX and GMAX categorical models are also more significant and predictive than corresponding models built in our previous QSAR studies of LLNA skin-sensitization measures...
  37. ncbi 4D-fingerprint categorical QSAR models for skin sensitization based on the classification of local lymph node assay measures
    Yi Li
    Laboratory of Molecular Modeling and Design MC 781, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612 7231, USA
    Chem Res Toxicol 20:114-28. 2007
    ..0% to 86.7%, whereas that of the PLS-logistic regression models ranges from 73.3% to 80.0%. The QSAR models are made up of 4D-fingerprints related to aromatic atoms, hydrogen bond acceptors, and negatively partially charged atoms...
  38. ncbi Categorical QSAR Models for skin sensitization based upon local lymph node assay classification measures part 2: 4D-fingerprint three-state and two-2-state logistic regression models
    Yi Li
    Laboratory of Molecular Modeling and Design MC 781, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612 7231, USA
    Toxicol Sci 99:532-44. 2007
    ....